lpca Laboratories Ltd. has embarked on a significant partnership with Omexa Formulary Pvt. Ltd. through a Technology Transfer Agreement aimed at advancing a biosimilar clone, refining processes, and transferring knowledge for global market penetration.
This collaboration empowers Omexa to steer the development of an anti-cancer biosimilar from its nascent stages through clinical trials and eventual commercial release. Such an alliance not only augments Omexa’s capabilities in biosimilar development but also solidifies its position in the biotech industry.
Pranay Godha, Managing Director and CEO of lpca Laboratories, underscores the strategic significance of this partnership, emphasizing its potential to lay a robust groundwork for anti-cancer and anti-inflammatory monoclonal antibody product development. Furthermore, he highlights the broader impact of this collaboration, stressing lpca’s commitment to furnishing affordable, high-quality biologic medications to address the pressing global need for treating chronic illnesses.
Dr. Nate Ramanathan, Managing Director & CEO of Omexa Formulary, echoes the sentiment of partnership, expressing confidence in lpca’s reputation as a dependable pharmaceutical entity. He emphasizes the invaluable expertise and technology that lpca brings to the table, which will empower Omexa to fulfill its mission of providing accessible, top-notch biologic drugs to a broad demographic. Dr. Ramanathan underscores Omexa’s dedication to its core values of affordability and quality, which will be upheld through innovative R&D and manufacturing methodologies.
This collaboration between lpca Laboratories and Omexa Formulary represents a symbiotic relationship geared towards advancing biosimilar development, ensuring global standards of quality, and ultimately enhancing accessibility to life-saving medications for patients worldwide.